Nasdaq
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Predictive Oncology Inc. focuses on developing personalized cancer therapies using artificial intelligence (AI) The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures.
Roles derived from SEC Form 4 filings.
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.4M | $1.5M | $492,596.00 | $84,812.00 | $125,284.00 |
| Gross profit | $805,080.00 | $933,656.00 | $1.0M | $297,491.00 | $6,527.00 | — |
| Operating income | -$25.4M | -$20.4M | -$26.0M | -$11.1M | -$10.3M | -$180.9M |
| Net income | -$25.9M | -$19.7M | -$25.7M | -$14.0M | -$12.7M | -$233.1M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$12.3M | -$12.2M | -$12.4M | -$13.2M | — | — |
| Free cash flow | -$12.6M | -$13.1M | -$12.8M | -$13.2M | — | — |
| Gross margin | 64.3% | 65.7% | 66.4% | 60.4% | 7.7% | — |
| Operating margin | -2025.1% | -1437.9% | -1729.3% | -2263.4% | -12149.1% | -144404.5% |
| Net margin | -2067.0% | -1383.6% | -1709.6% | -2838.8% | -14932.3% | -186053.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $67,255.00 | $3,907.00 | $8,792.00 | $110,310.00 | $2,682.00 | $3,618.00 | $8,674.00 | $35,311.00 |
| Gross profit | $53,397.00 | -$7,270.00 | -$22,025.00 | $65,192.00 | -$15,539.00 | -$4,738.00 | — | — |
| Operating income | -$2.5M | -$2.2M | -$2.1M | -$2.3M | -$2.7M | -$3.3M | -$172.7M | -$7.7M |
| Net income | -$3.2M | -$3.1M | -$2.2M | -$2.4M | -$2.1M | -$77.7M | -$150.9M | -$7.7M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$3.2M | — | — | — | — | — | — | — |
| Free cash flow | -$3.2M | — | — | — | — | — | — | — |
| Gross margin | 79.4% | -186.1% | -250.5% | 59.1% | -579.4% | -131.0% | — | — |
| Operating margin | -3664.6% | -55296.7% | -23848.9% | -2073.3% | -99174.8% | -90654.1% | -1990880.1% | -21887.5% |
| Net margin | -4730.1% | -79208.9% | -24676.9% | -2214.6% | -77198.4% | -2146264.3% | -1740028.0% | -21831.6% |
Consensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-29 | Zhu Theodore | Award | 11,250 | $6.61 | $74,362.50 | filing |
| 2026-05-28 | Zhu Theodore | Award | 3,750 | $6.61 | $24,787.50 | filing |
| 2026-05-14 | Blacher Joshua· Co-Chief Financial Officer | Award | 9,389 | $0.00 | $0.00 | filing |
| 2026-04-20 | Zhu Theodore | Award | 5,144 | $0.00 | $0.00 | filing |
| 2026-04-20 | Nuzum Charles Lee Sr | Award | 14,082 | $0.00 | $0.00 | filing |
| 2026-04-20 | ST. CLAIR GREGORY SR | Award | 9,419 | $0.00 | $0.00 | filing |
| 2026-04-20 | Hawryluk Matthew | Award | 6,782 | $0.00 | $0.00 | filing |
| 2026-04-20 | HANDLEY DANIEL E | Award | 5,663 | $0.00 | $0.00 | filing |
| 2026-03-06 | Rao Veena | Award | 4,197 | $0.00 | $0.00 | filing |
| 2026-03-06 | Matthews Shawn | Award | 1,166 | $0.00 | $0.00 | filing |
| 2026-02-05 | Vennare Raymond F· Chief Executive Officer | Tax withholding | 6,758 | $2.59 | $17,503.22 | filing |
| 2025-12-10 | Vennare Raymond F· Chief Executive Officer | Award | 20,000 | $0.00 | $0.00 | filing |
| 2025-11-28 | Vennare Raymond F· Chief Executive Officer | Tax withholding | 2,373 | $5.90 | $14,000.70 | filing |
| 2025-09-09 | CHUNG-WELCH NANCY | Award | 64,680 | $0.00 | $0.00 | filing |
| 2025-09-09 | HANDLEY DANIEL E | Award | 64,680 | $0.00 | $0.00 | filing |
| 2025-09-09 | Hawryluk Matthew | Award | 64,680 | $0.00 | $0.00 | filing |
| 2025-09-09 | Rao Veena | Award | 64,680 | $0.00 | $0.00 | filing |
| 2025-09-09 | ST. CLAIR GREGORY SR | Award | 64,680 | $0.00 | $0.00 | filing |
| 2025-09-09 | Nuzum Charles Lee Sr | Award | 64,680 | $0.00 | $0.00 | filing |
| 2025-09-09 | Blacher Joshua· Interim CFO | Award | 97,000 | $0.00 | $0.00 | filing |
| 2025-09-09 | Vennare Raymond F· Chief Executive Officer | Award | 124,959 | $0.00 | $0.00 | filing |
Latest 21 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.